An Open-label Study to Assess the Safety and Tolerability of ISIS 396443 in Patients With Spinal Muscular Atrophy Who Previously Participated in 396443-CS2 or 396443-CS10
Latest Information Update: 10 Aug 2021
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions
- Sponsors Biogen; Ionis Pharmaceuticals
- 22 Jun 2021 Results from NCT01703988; NCT02052791 and NCT02594124, assessing long term improved/maintained motor function in nusinersen treated children with later onset Spinal-muscular-atrophy, presented at the 7th Congress of the European Academy of Neurology
- 10 Jun 2021 According to Biogen media release, results of post hoc analysis of CS2-CS12 and SHINE extension study are being presented at the virtual Cure SMA Research & Clinical Care Meeting.
- 10 Jun 2021 Results of post hoc analysis of CS2-CS12 and SHINE extension study published in the Media Release